Anika Therapeutics (ANIK) Share-based Compensation (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Share-based Compensation of $1.8 million for Q2 2026, down 28.06% year-over-year from $2.5 million in Q2 2025, and down 44.45% quarter-over-quarter from $3.3 million in Q1 2026.
Anika Therapeutics (ANIK) Share-based Compensation (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Share-based Compensation for 17 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Share-based Compensation fell 28.06% year-over-year to $1.8 million; the TTM figure through Jun 2026 stood at $9.8 million (down 12.38% YoY), while the FY2025 annual figure was $10.2 million, down 22.19% from the prior year.
- Share-based Compensation fell to $1.8 million in Q2 2026 per ANIK's latest filing, from $3.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.1 million in Q2 2022 and bottomed at $7000.0 in Q1 2023.
- Historically, Share-based Compensation has averaged $2.3 million across 5 years, with a median of $2.7 million in 2022.
- Annual changes were most pronounced in 2023 — Share-based Compensation sank 99.26% — and 2025, when it jumped 12921.74%.
- Anika Therapeutics' Share-based Compensation stood at $2.7 million in 2022, then soared by 39.95% to $3.8 million in 2023, then plunged by 40.89% to $2.3 million in 2024, then rose by 14.86% to $2.6 million in 2025, then decreased by 29.23% to $1.8 million in 2026.
- Business Quant data shows ANIK's Share-based Compensation at $1.8 million in Q2 2026, $3.3 million in Q1 2026, and $2.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn | 1.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.83 Mn |
| Jun 30, 2026 | 1.83 Mn |
| Mar 31, 2026 | 3.30 Mn |
| Mar 31, 2026 | 3.30 Mn |
| Dec 31, 2025 | 2.59 Mn |
| Dec 31, 2025 | 2.59 Mn |
| Sep 30, 2025 | 2.08 Mn |
| Sep 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 2.55 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Mar 31, 2024 | 23,000.00 |
| Mar 31, 2024 | 23,000.00 |